Fae went to school the day before her family learned she had cancer. Everything seemed so normal, and then…it wasn’t. Her ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

Oct. 7, 2024 — Fratricide-resistant CD7 CAR-T therapy by NUS proves effective ... risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Blinatumomab, which recently completed clinical trials and has won approval from the FDA, is a drug designed to treat acute lymphoblastic leukemia ... the body’s T-cells, a type of white ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...